MCID: SLP001
MIFTS: 46

Sleeping Sickness

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 51 56 3 14
African Trypanosomiasis 12 56 3 69
African Sleeping Sickness 12
Trypanosomiasis, African 42
Trypanosomiasis African 52

Characteristics:

Orphanet epidemiological data:

56
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD10 33 B56 B56.9
ICD9CM 35 086.5
MeSH 42 D014353
NCIt 47 C84541
Orphanet 56 ORPHA3385
MESH via Orphanet 43 D014353
UMLS via Orphanet 70 C0041228
ICD10 via Orphanet 34 B56.0 B56.1 B56.9
UMLS 69 C0041228

Summaries for Sleeping Sickness

NINDS : 51 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to malaria and trypanosomiasis, human east-african. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are African trypanosomiasis and Metabolism. The drugs Clonidine and Trazodone have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and heart.

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness," is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
id Related Disease Score Top Affiliating Genes
1 malaria 29.1 GAPDH IL10 IL6 NOS2 ODC1 SRM
2 trypanosomiasis, human east-african 11.0
3 trypanosomiasis, human west-african 11.0
4 peroneal nerve paralysis 10.6 IL10 IL6
5 infancy electroclinical syndrome 10.5 IL10 IL6
6 idiopathic dilatation of the pulmonary artery 10.4 IL10 NOS2
7 ethmoid sinus adenocarcinoma 10.4 IL10 IL6
8 lennox-gastaut syndrome 10.4 ABCB7 MDH2
9 trypanosomiasis 10.4
10 ragweed sensitivity 10.4 IL10 IL6 NOS2
11 keratomalacia 10.3 IL10 IL6 NOS2
12 colon adenocarcinoma 10.3 IL10 IL6 MDH2
13 prostate carcinoma in situ 10.2 IL10 IL6 NOS2
14 discoid lupus erythematosus of eyelid 10.2 IL10 NOS2 SRM
15 mucocutaneous leishmaniasis 10.1 IL10 NOS2 PGD
16 psychologic vaginismus 10.1 NOS2 ODC1
17 alcohol abuse 10.1 IL10 IL6 TF
18 leishmaniasis 10.1
19 calcinosis 10.1 APOL1 IL6 TF
20 chagas disease 10.0
21 lacrimal system cancer 10.0 IL10 IL6 TF
22 granulomatous orchitis 10.0 IL10 IL6 TF
23 xeroderma pigmentosum, group f 10.0 ABCB7 TF
24 drug rash with eosinophilia and systemic symptoms 9.9 APOA1 IL10 IL6
25 choroiditis 9.9
26 tricho onychic dysplasia 9.9 APOA1 IL10 IL6
27 detrusor sphincter dyssynergia 9.9 AMD1 IL10 IL6 NOS2 ODC1
28 encephalopathy 9.9
29 cerebritis 9.9
30 early-onset zonular cataract 9.8 IL10 IL6 NOS2 TF
31 myelophthisic anemia 9.7 APOA1 IL10 IL6
32 microscopic colitis 9.7 IL10 IL6 NOS2
33 narcolepsy 9.6
34 visceral leishmaniasis 9.6
35 encephalitis 9.6
36 hepatitis c virus 9.6
37 hepatitis 9.6
38 rabies 9.6
39 hepatitis c 9.6
40 hypogonadism 9.6
41 viral encephalitis 9.6
42 neuronitis 9.6
43 hyperpigmentation of eyelid 9.4 AMD1 APOL1 IL10 IL6 ODC1 TF
44 hepatic adenoma, somatic 8.9 APOA1 IL10 IL6 NOS2 TF
45 eyelid degenerative disease 5.0 ABCB7 AMD1 APOA1 APOL1 CTPS1 GAPDH

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Cyclobenzaprine Approved Phase 4 303-53-7 2895
5
Sodium oxybate Approved Phase 4,Phase 2 502-85-2 5360545
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
8
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
9
Acetazolamide Approved, Vet_approved Phase 4,Phase 1 59-66-5 1986
10
Ziprasidone Approved Phase 4 146939-27-7 60854
11
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
12
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
13
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
14
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
15
Zolpidem Approved Phase 4 82626-48-0 5732
16
Ethanol Approved Phase 4 64-17-5 702
17
Topiramate Approved Phase 4 97240-79-4 5284627
18
Histamine Approved, Investigational Phase 4,Phase 3 75614-87-8, 51-45-6 774
19
Benzocaine Approved Phase 4,Phase 1 1994-09-7, 94-09-7 2337
20
Glycerol Approved, Investigational Phase 4 56-81-5 753
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
22
Metformin Approved Phase 4 657-24-9 14219 4091
23
Methazolamide Approved Phase 4 554-57-4 4100
24
Nifedipine Approved Phase 4 21829-25-4 4485
25
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 73-31-4 896
26
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 70-26-8, 3184-13-2 6262 389
27 tannic acid Approved, Nutraceutical Phase 4,Phase 1
28 Nifurtimox Investigational Phase 4,Phase 3,Phase 2 23256-30-6
29 Adrenergic Agents Phase 4,Phase 2
30 Adrenergic Agonists Phase 4
31 Adrenergic alpha-2 Receptor Agonists Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
34 Antihypertensive Agents Phase 4
35 Autonomic Agents Phase 4,Phase 3,Phase 2
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Sympatholytics Phase 4
39 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antidepressive Agents Phase 4,Phase 2
41 Antidepressive Agents, Second-Generation Phase 4
42 Antipsychotic Agents Phase 4,Phase 3,Phase 1
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
44 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
45 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
46 Quetiapine Fumarate Phase 4,Phase 1 111974-72-2
47
Serotonin Phase 4,Phase 2 50-67-9 5202
48 Serotonin Agents Phase 4,Phase 2
49 Serotonin Uptake Inhibitors Phase 4
50 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 228)

id Name Status NCT ID Phase Drugs
1 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
2 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
3 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans Unknown status NCT01662297 Phase 4 Quetiapine;Trazodone
4 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
5 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
6 Melatonin for Delirium Prophylaxis Unknown status NCT02282241 Phase 4 Melatonin
7 Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
8 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4 bupropion-SR
9 A Pilot Study of Effect of Dexmedetomidine on Sleep and Inflammation in Critically Ill Patients Completed NCT00405847 Phase 4 Dexmedetomidine
10 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
11 An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression Completed NCT00835107 Phase 4 ziprasidone hydrochloride;placebo
12 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
13 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
14 An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients Completed NCT00520507 Phase 4 Olanzapine;Placebo
15 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Acetazolamide
16 Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients Completed NCT01149577 Phase 4 Olanzapine
17 SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) Completed NCT02055898 Phase 4 Sodium Oxybate
18 Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients? Completed NCT01791296 Phase 4 Dexmedetomidine
19 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
20 Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA Completed NCT01024192 Phase 4 ZOLPIDEM SL800750
21 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
22 Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder Completed NCT00552760 Phase 4 Ramelteon;Placebo
23 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
24 Oral Melatonin in Critically Ill High-risk Patients Completed NCT00470821 Phase 4 Oral melatonin 3mg BID;Placebo
25 Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Recruiting NCT03031626 Phase 4
26 Ramelteon for Treatment of Insomnia in Cirrhosis Recruiting NCT03091738 Phase 4 Ramelteon Pill
27 The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children Recruiting NCT02743663 Phase 4 salbutamol
28 Sleep Intervention During Acute Lung Injury Active, not recruiting NCT01050699 Phase 4 Dexmedetomidine;Midazolam and Fentanyl
29 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4 Nifedipine extended release;Methazolamide;Metformin;Placebo;Nitrite
30 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
31 Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome Terminated NCT00498485 Phase 4 Placebo;Sodium Oxybate
32 Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea Unknown status NCT01680939 Phase 3 Morphine;Ibuprofen
33 The Efficacy of the Caregiver Psychoeducational Consultation Program Unknown status NCT01001884 Phase 2, Phase 3
34 Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
35 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Completed NCT01589289 Phase 3
36 Trial of Melatonin to Improve Sleep in Children With Epilepsy and Neurodevelopmental Disabilities Completed NCT01161108 Phase 3 Fast Release Melatonin (FR MLT);Fast Release Placebo;Timed Release Melatonin (TR MLT);Timed Release Placebo
37 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study Completed NCT00515177 Phase 2, Phase 3 eszopiclone
38 "NAVA-PAV" Study: a Cross-over Comparative Study of 2 Advanced Modes Completed NCT01607723 Phase 3
39 "VARIABLE-PSV" Study Completed NCT01580956 Phase 3
40 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
41 CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Completed NCT01636791 Phase 3
42 CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care Completed NCT01667809 Phase 3
43 Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance Completed NCT00748098 Phase 3 GSK1838262 Extended Release Tablets;Placebo
44 Rapid Tranquillization Trial: TREC-India II Completed NCT00455234 Phase 3 Intramuscular Olanzepine 10 mg;Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg
45 Shingles Prevention Study Completed NCT00007501 Phase 3
46 Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
47 Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
48 Morphine in Moderate Obstructive Sleep Apnoea Recruiting NCT03127800 Phase 3 Morphine sulphate
49 Insomnia Self-Management in Heart Failure Recruiting NCT02660385 Phase 2, Phase 3
50 Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia Recruiting NCT02469389 Phase 2, Phase 3

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

39
Testes, Eye, Heart, Lung, Liver, Brain, Amygdala

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 559)
id Title Authors Year
1
Loop-Mediated Isothermal Amplification Test for Trypanosoma gambiense Group 1 with Stem Primers: A Molecular Xenomonitoring Test for Sleeping Sickness. ( 28321260 )
2017
2
Elimination of sleeping sickness in Uganda could be jeopardised by conflict in South Sudan. ( 27955775 )
2017
3
Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo. ( 28056016 )
2017
4
Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC. ( 28279451 )
2017
5
Cell Cycle Inhibition To Treat Sleeping Sickness. ( 28928213 )
2017
6
Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). ( 28750007 )
2017
7
New developments in probing and targeting protein acylation in malaria, leishmaniasis and African sleeping sickness. ( 28270257 )
2017
8
The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness. ( 26807135 )
2016
9
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies. ( 26881924 )
2016
10
Silent Human Trypanosoma brucei gambiense Infections around the Old Gboko Sleeping Sickness Focus in Nigeria. ( 26941995 )
2016
11
Trypanosoma brucei Invasion and T-Cell Infiltration of the Brain Parenchyma in Experimental Sleeping Sickness: Timing and Correlation with Functional Changes. ( 28002454 )
2016
12
A targeted door-to-door strategy for sleeping sickness detection in low-prevalence settings in CA'te d'Ivoire. ( 27849517 )
2016
13
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. ( 27501246 )
2016
14
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness. ( 27720295 )
2016
15
Analysis of a model of gambiense sleeping sickness in humans and cattle. ( 27296784 )
2016
16
African sleeping sickness. ( 27723399 )
2016
17
Novel Financing Model for Neglected Tropical Diseases: Development Impact Bonds Applied to Sleeping Sickness and Rabies Control. ( 27855156 )
2016
18
Tsetse Control and the Elimination of Gambian Sleeping Sickness. ( 27128795 )
2016
19
Transmission Dynamics of Rhodesian Sleeping Sickness at the Interface of Wildlife and Livestock Areas. ( 27262917 )
2016
20
Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing? ( 26998514 )
2016
21
Survey on Trypanosoma spp. infection of dogs in Gabon and its epidemiological implications for sleeping sickness. ( 26947985 )
2016
22
Xenomonitoring of sleeping sickness transmission in Campo (Cameroon). ( 27071554 )
2016
23
Whole genome sequencing shows sleeping sickness relapse is due to parasite regrowth and not reinfection. ( 26834831 )
2016
24
Carbohydrate-Binding Non-Peptidic Pradimicins for the Treatment of Acute Sleeping Sickness in Murine Models. ( 27662652 )
2016
25
Spatial distribution and trypanosome infection of tsetse flies in the sleeping sickness focus of Zimbabwe in Hurungwe District. ( 27884172 )
2016
26
Global Profiling and Inhibition of Protein Lipidation in Vector and Host Stages of the Sleeping Sickness Parasite Trypanosoma brucei. ( 27331140 )
2016
27
Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. ( 26882015 )
2016
28
Simulating the elimination of sleeping sickness with an agent-based model. ( 28008825 )
2016
29
Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. ( 25642701 )
2015
30
Evaluation of trypanocidal activity of combinations of anti-sleeping sickness drugs with cysteine protease inhibitors. ( 25662707 )
2015
31
Challenges facing the elimination of sleeping sickness in west and central Africa: sustainable control of animal trypanosomiasis as an indispensable approach to achieve the goal. ( 26671582 )
2015
32
Genetic diversity and population structure of Trypanosoma brucei in Uganda: implications for the epidemiology of sleeping sickness and Nagana. ( 25695634 )
2015
33
In silico drug re-purposing against African sleeping sickness using GlcNAc-PI de-N-acetylase as an experimental target. ( 26476127 )
2015
34
Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. ( 26267814 )
2015
35
Alterations of orexinergic and melanin-concentrating hormone neurons in experimental sleeping sickness. ( 25595977 )
2015
36
Costs of using "tiny targets" to control Glossina fuscipes fuscipes, a vector of gambiense sleeping sickness in Arua District of Uganda. ( 25811956 )
2015
37
Reducing Human-Tsetse Contact Significantly Enhances the Efficacy of Sleeping Sickness Active Screening Campaigns: A Promising Result in the Context of Elimination. ( 26267667 )
2015
38
Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo. ( 25535944 )
2015
39
Ecotype evolution in Glossina palpalis subspecies, major vectors of sleeping sickness. ( 25775377 )
2015
40
Trypanosome infection rates in tsetse flies in the "silent" sleeping sickness focus of Bafia in the Centre Region in Cameroon. ( 26458386 )
2015
41
Deadly Flies, Poor Profits and Veterinary Pharmaceuticals: Sustaining the Control of Sleeping Sickness in Uganda. ( 26457971 )
2015
42
Baited-boats: an innovative way to control riverine tsetse, vectors of sleeping sickness in West Africa. ( 25928366 )
2015
43
From health advice to taboo: community perspectives on the treatment of sleeping sickness in the democratic republic of congo, a qualitative study. ( 25856578 )
2015
44
Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. ( 25512417 )
2015
45
Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. ( 26490037 )
2015
46
Clinical profiles, disease outcome and co-morbidities among T. b. rhodesiense sleeping sickness patients in Uganda. ( 25719539 )
2015
47
Sleeping sickness and its relationship with development and biodiversity conservation in the Luangwa Valley, Zambia. ( 25879414 )
2015
48
Interleukin (IL)-6 and IL-10 Are Up Regulated in Late Stage Trypanosoma brucei rhodesiense Sleeping Sickness. ( 26090964 )
2015
49
Comparative analysis of cerebrospinal fluid from the meningo-encephalitic stage of T. b. gambiense and rhodesiense sleeping sickness patients using TMT quantitative proteomics. ( 26306311 )
2015
50
Changing landscapes, changing practice: Negotiating access to sleeping sickness services in a post-conflict society. ( 24679924 )
2014

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to KEGG:

37
id Name Kegg Source Accession
1 African trypanosomiasis hsa05143

Pathways related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 ABCB7 AMD1 APOA1 CTPS1 GAPDH MDH2
2 11.83 GAPDH IL10 IL6 TF
3
Show member pathways
11.74 AMD1 MDH2 SRM
4 11.62 IL10 IL6 NOS2
5 11.61 HSPA8 IL10 IL6 NOS2
6 11.57 MDH2 ODC1 SRM
7 11.46 IL10 IL6 NOS2
8 11.45 GAPDH IL6 NOS2 TF
9 11.39 IL10 IL6 NOS2
10
Show member pathways
11.01 AMD1 NOS2 ODC1 SRM
11
Show member pathways
10.9 ODC1 SRM
12 10.77 APOA1 APOL1
13 10.47 APOA1 APOL1 IL10 IL6

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule lumen GO:0034774 9.33 APOA1 HSPA8 TF
2 high-density lipoprotein particle GO:0034364 9.32 APOA1 APOL1
3 very-low-density lipoprotein particle GO:0034361 9.26 APOA1 APOL1
4 endoplasmic reticulum lumen GO:0005788 9.26 APOA1 APOL1 IL6 TF
5 blood microparticle GO:0072562 8.92 APOA1 APOL1 HSPA8 TF

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.76 APOA1 APOL1 IL6 TF
2 response to drug GO:0042493 9.73 APOA1 CTPS1 IL10 IL6
3 cellular response to lipopolysaccharide GO:0071222 9.65 IL10 IL6 NOS2
4 cellular protein metabolic process GO:0044267 9.62 APOA1 APOL1 IL6 TF
5 lipoprotein metabolic process GO:0042157 9.51 APOA1 APOL1
6 defense response to protozoan GO:0042832 9.49 IL10 IL6
7 cellular response to hepatocyte growth factor stimulus GO:0035729 9.4 IL10 IL6
8 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.37 APOA1 IL10
9 negative regulation of cytokine secretion involved in immune response GO:0002740 9.26 APOA1 IL10
10 spermidine biosynthetic process GO:0008295 9.16 AMD1 SRM
11 polyamine biosynthetic process GO:0006596 9.13 AMD1 ODC1 SRM
12 polyamine metabolic process GO:0006595 8.8 AMD1 ODC1 SRM

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....